Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APS03118 in RET-altered solid tumors
NCT05653869Phase 1Active, not recruiting
- Sponsor
- Applied Pharmaceutical Science, Inc.
- Start
- Feb 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APS03118 in solid tumor, sponsored by Applied Pharmaceutical Science, Inc. Primary endpoints: Dose-Limiting Toxicities at 28 days, Maximum Tolerated Dose at 15 months and 1 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
APS03118
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05653869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653869.